This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Oncopeptides (ONCO BTA) Stock Overview

A biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. More details

ONCO BTA fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 78.3% below our estimate of its fair value

Revenue is forecast to grow 61.28% per year

Earnings have grown 45.1% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Negative shareholders equity

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap (SEK411M)

+ 1 more risk

ONCO BTA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Oncopeptides AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Oncopeptides
Historical stock prices
Current Share Price	SEK 1.46
52 Week High	SEK 2.00
52 Week Low	SEK 1.42
Beta	-1.82
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-12.05%

Recent updates

Shareholder Returns

	ONCO BTA	SE Biotechs	SE Market
7D	-1.7%	4.2%	-0.8%
1Y	n/a	28.5%	10.3%

Return vs Industry: Insufficient data to determine how ONCO BTA performed against the Swedish Biotechs industry.

Return vs Market: Insufficient data to determine how ONCO BTA performed against the Swedish Market.

Price Volatility

Is ONCO BTA's price volatile compared to industry and market?
ONCO BTA volatility
ONCO BTA Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.4%
Market Average Movement	6.1%
10% most volatile stocks in SE Market	13.3%
10% least volatile stocks in SE Market	3.4%

Stable Share Price: ONCO BTA's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: Insufficient data to determine ONCO BTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	75	Sofia Heigis	www.oncopeptides.com/sv

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells.

Oncopeptides AB (publ) Fundamentals Summary

How do Oncopeptides's earnings and revenue compare to its market cap?
ONCO BTA fundamental statistics
Market cap	SEK 410.70m
Earnings (TTM)	-SEK 249.58m
Revenue (TTM)	SEK 71.12m

5.8x

P/S Ratio

-1.6x

P/E Ratio

Is ONCO BTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ONCO BTA income statement (TTM)
Revenue	SEK 71.12m
Cost of Revenue	SEK 2.45m
Gross Profit	SEK 68.67m
Other Expenses	SEK 318.25m
Earnings	-SEK 249.58m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Apr 28, 2026

Earnings per share (EPS)	-0.92
Gross Margin	96.55%
Net Profit Margin	-350.94%
Debt/Equity Ratio	-215.1%

How did ONCO BTA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/03/25 14:52
End of Day Share Price	2026/03/23 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oncopeptides AB (publ) is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Erik Hultgård	Carnegie Investment Bank AB
Patrik Ling	DNB Carnegie
Erik Hultgård	DNB Carnegie

Oncopeptides AB (publ)OM:ONCO BTA Stock Report